The 3 prime paradigm of the miR-200 family and other microRNAs.
The number of predicted human microRNAs in Sanger miRBase currently stands at over a thousand, with each of these in turn predicted to target numerous mRNAs. However, those microRNAs for which mRNA targets have been evaluated, verified and reported in the literature are still in the minority and the bulk of microRNA/mRNA interactions are yet to be confirmed. Confirmation of microRNA interaction with predicted mRNA targets represents a considerable undertaking, made more complex by potential synergistic effects of multiple microRNAs and the three possible outcomes (translational repression, degradation or a mixture of both). In addition, contrasting results obtained when either stably expressing or transiently transfecting members of the miR-200 family illustrate limitations in the verification methods currently in use. In this article we suggest that instead of allowing computational predictions to drive investigation, it would be desirable, when possible, to systematically evaluate microRNA targets using inducible, stable, ectopic expression. The advantage of stable lines ectopically expressing microRNA(s) is that they allow an analysis of changes to both the proteome and the transcriptome. This would allow verification of targets, improve the design of prediction algorithms and greatly increase our understanding of the outcome of microRNA/mRNA interaction.
Pfizer, Division of Molecular Medicine, Groton, CT, USA. graham.brock@pfizer.com
Graham J
GJ
Brock
Sterghios
S
Moschos
Simon D
SD
Spivack
Gregory J
GJ
Hurteau
D000465:Algorithms; D019295:Computational Biology / Q000379:methods*; D020869:Gene Expression Profiling; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*; D008957:Models, Genetic; D012333:RNA, Messenger / Q000378:metabolism
D035683:MicroRNAs; D012333:RNA, Messenger
Bioinformatics. 2009 Dec 1;25(23):3049-55
19789267
Mol Cell. 2010 Jun 25;38(6):908-15
20620960
Cold Spring Harb Symp Quant Biol. 2006;71:369-76
17381319
Nucleic Acids Res. 2009 Sep;37(16):5498-510
19578061
Nat Genet. 2002 Apr;30(4):363-4
11896390
EMBO Rep. 2008 Jun;9(6):582-9
18483486
Cell. 2003 Dec 26;115(7):787-98
14697198
J Virol. 2010 Jul;84(13):6615-25
20427538
J Immunol. 2008 Apr 15;180(8):5689-98
18390754
Nat Methods. 2007 Sep;4(9):721-6
17694064
Cell Cycle. 2006 Sep;5(17):1951-6
16929162
Nucleic Acids Res. 2007;35(7):2333-42
17389647
Nature. 2009 Jul 23;460(7254):479-86
19536157
Cell Cycle. 2009 Jul 1;8(13):2064-9
19502803
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18255-60
17108080
Cancer Res. 2007 Sep 1;67(17):7972-6
17804704
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19231-6
20974915
RNA Biol. 2009 Sep-Oct;6(4):406-11
19617709
Nat Cell Biol. 2008 May;10(5):593-601
18376396
Nat Genet. 2001 Dec;29(4):365-71
11726920